RxDoctor Payments DataLook up a doctor →

Julian de Bruyn Kops, MD

Family Medicine · Idaho Falls, IDNPI 1922086552

Payments from drug & device makers

$32,412in general payments, 2019–2025

Across 763 payments — averaging $42.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$13K
  • AstraZeneca$7K
  • AbbVie$2K
  • Novo Nordisk$1K
  • Lilly USA, LLC$1K
  • Novartis$809
  • plus $6K from 41 others

What the payments were for

  • Speaking & faculty fees$12,95040%
  • Travel & lodging$2,3287%
  • Food & beverage$16,94952%
  • Education$1851%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$32,412 in reported general payments places this provider in the 95th percentile of 803 family medicine providers in Idaho.

See all family medicine providers in Idaho

Medicare billing

Part B allowed, 2024
$134,068
Medicare patients
205
Services billed
1,833

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide480$545,422
OzempicSemaglutide91$115,247
EliquisApixaban49$75,612
FarxigaDapagliflozin Propanediol50$64,912
Tresiba Flextouch U-200Insulin Degludec37$47,558
JardianceEmpagliflozin41$43,634
TrulicityDulaglutide38$41,370
Repatha SureclickEvolocumab37$36,331
InvokanaCanagliflozin15$24,943
JanuviaSitagliptin Phosphate15$21,197
SymbicortBudesonide/Formoterol Fumarate15$8,560
Breo ElliptaFluticasone/Vilanterol11$8,359
Potassium Chloride122$4,317
Levothyroxine Sodium375$4,172
Ezetimibe203$4,038

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$1,061$586,792518 claims
Novo NordiskOzempic$1,424$115,24791 claims
PfizerEliquis, Paxlovid$576$77,04161 claims
AstraZenecaFarxiga, Symbicort$7,455$73,47165 claims
Boehringer IngelheimJardiance$490$43,63441 claims
Johnson & JohnsonInvokana$327$24,94315 claims
MerckJanuvia$424$21,19715 claims
GSKBreo Ellipta$764$8,35911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 803 family medicine providers in Idaho.

Other family medicine in Idaho Falls

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →